Taking a young person’s plasma and infusing it into an older person to ward off aging -- a therapy that’s fascinated some of the biggest names in Silicon Valley -- has no proven clinical benefit, the Food and Drug Administration said.
The agency issued a safety alert on Tuesday about the infusion of plasma from young donors for the prevention of conditions such as aging or memory loss, or for the treatment of such conditions as dementia, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, heart disease or post‐traumatic stress disorder.
“There is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat or prevent these conditions, and there are risks associated with the use of any plasma product,” the FDA said in a statement from Commissioner Scott Gottlieb and Peter Marks, head of the agency’s biologics center.
https://www.bloomberg.com/news/articles/2019-02-19/beware-of-buying-young-people-s-blood-to-prevent-aging-fda-says [bloomberg.com]